A MultiCentre, Phase III, Open-Label, Randomized Study In Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia To Evaluate The Benefit Of GDC-0199 (ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab

Project: Research

Project Details

Project Description

SERP Reference Number: HREC/14/PMCC/4SSA Reference Number: SSA/14/SHA/20
Monash Health HREC Ref: 14152X
Effective start/end date19/05/2018/05/25


  • clinical trial
  • phase 3 study
  • treatment efficacy
  • treatment safety
  • lymphoma
  • leukemia